Skip to main content
SpringerLink
Log in

IBS

Amitriptyline as second-line treatment for IBS in primary care settings

  • In Brief
  • Published:

From Nature Reviews Gastroenterology & Hepatology

View current issue Sign up to alerts

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

Original article

  • Ford, A. C. et al. Amitriptyline at low-dose and titrated for irritable bowel syndrome as second-line treatment in primary care (ATLANTIS): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 402, 1773–1785 (2023)

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Nature Reviews Gastroenterology & Hepatology http://www.nature.com/nrgastro/

    Katrina Ray

Authors
  1. Katrina Ray
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Katrina Ray.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Ray, K. Amitriptyline as second-line treatment for IBS in primary care settings. Nat Rev Gastroenterol Hepatol 21, 2 (2024). https://doi.org/10.1038/s41575-023-00873-1

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/s41575-023-00873-1

  • Springer Nature Limited

Search

Navigation